Nuvectis Pharma, Inc. (NVCT)

NASDAQ: NVCT · Real-Time Price · USD

8.77

+0.01 (0.11%)

Feb 13, 2026, 4:00 PM EST - Market closed

Nuvectis Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	9.42	6.93	7.52	6.01	3.35
Research & Development	18.15	12.92	14.38	12.03	2.45
Operating Expenses	27.57	19.85	21.9	18.03	5.79
Operating Income	-27.57	-19.85	-21.9	-18.03	-5.79
Interest & Investment Income	1.13	0.85	0.64	0.15	0
EBT Excluding Unusual Items	-26.44	-19	-21.26	-17.89	-5.79
Other Unusual Items	-	-	-1	-1.2	-7.1
Pretax Income	-26.44	-19	-22.26	-19.09	-12.89
Net Income	-26.44	-19	-22.26	-19.09	-12.89
Preferred Dividends & Other Adjustments	2.43	-	-	-	-
Net Income to Common	-28.87	-19	-22.26	-19.09	-12.89
Shares Outstanding (Basic)	22	17	16	13	4
Shares Outstanding (Diluted)	22	17	16	13	4
Shares Change (YoY)	27.46%	10.01%	22.90%	196.55%	9.44%
EPS (Basic)	-1.32	-1.11	-1.43	-1.51	-3.02
EPS (Diluted)	-1.32	-1.11	-1.43	-1.51	-3.02
EBIT	-27.57	-19.85	-21.9	-18.03	-5.79

Updated Feb 11, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q